Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes.
Aged
Aged, 80 and over
Body Mass Index
COVID-19
/ complications
Cohort Studies
Comorbidity
Diabetes Mellitus
/ diagnosis
Female
France
/ epidemiology
Hospital Mortality
Hospitalization
/ statistics & numerical data
Humans
Intensive Care Units
/ statistics & numerical data
Length of Stay
/ statistics & numerical data
Male
Middle Aged
Pandemics
Prognosis
Retrospective Studies
Risk Factors
SARS-CoV-2
/ physiology
Severity of Illness Index
Treatment Outcome
acute respiratory distress syndrome
coronavirus disease 2019 (COVID-19)
diabetes
intensive care
mortality
outcome
Journal
Diabetes/metabolism research and reviews
ISSN: 1520-7560
Titre abrégé: Diabetes Metab Res Rev
Pays: England
ID NLM: 100883450
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
revised:
18
06
2020
received:
29
05
2020
accepted:
14
07
2020
pubmed:
20
7
2020
medline:
26
3
2021
entrez:
20
7
2020
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) is a rapidly progressing pandemic, with four million confirmed cases and 280 000 deaths at the time of writing. Some studies have suggested that diabetes is associated with a greater risk of developing severe forms of COVID-19. The primary objective of the present study was to compare the clinical features and outcomes in hospitalized COVID-19 patients with vs without diabetes. All consecutive adult patients admitted to Amiens University Hospital (Amiens, France) with confirmed COVID-19 up until April 21st, 2020, were included. The composite primary endpoint comprised admission to the intensive care unit (ICU) and death. Both components were also analysed separately in a logistic regression analysis and a Cox proportional hazards model. A total of 433 patients (median age: 72; 238 (55%) men; diabetes: 115 (26.6%)) were included. Most of the deaths occurred in non-ICU units and among older adults. Multivariate analyses showed that diabetes was associated neither with the primary endpoint (odds ratio (OR): 1.12; 95% confidence interval (CI): 0.66-1.90) nor with mortality (hazard ratio: 0.73; 95%CI: 0.40-1.34) but was associated with ICU admission (OR: 2.06; 95%CI 1.09-3.92, P = .027) and a longer length of hospital stay. Age was negatively associated with ICU admission and positively associated with death. Diabetes was prevalent in a quarter of the patients hospitalized with COVID-19; it was associated with a greater risk of ICU admission but not with a significant elevation in mortality. Further investigation of the relationship between COVID-19 severity and diabetes is warranted.
Sections du résumé
BACKGROUND
Coronavirus disease 2019 (COVID-19) is a rapidly progressing pandemic, with four million confirmed cases and 280 000 deaths at the time of writing. Some studies have suggested that diabetes is associated with a greater risk of developing severe forms of COVID-19. The primary objective of the present study was to compare the clinical features and outcomes in hospitalized COVID-19 patients with vs without diabetes.
METHODS
All consecutive adult patients admitted to Amiens University Hospital (Amiens, France) with confirmed COVID-19 up until April 21st, 2020, were included. The composite primary endpoint comprised admission to the intensive care unit (ICU) and death. Both components were also analysed separately in a logistic regression analysis and a Cox proportional hazards model.
RESULTS
A total of 433 patients (median age: 72; 238 (55%) men; diabetes: 115 (26.6%)) were included. Most of the deaths occurred in non-ICU units and among older adults. Multivariate analyses showed that diabetes was associated neither with the primary endpoint (odds ratio (OR): 1.12; 95% confidence interval (CI): 0.66-1.90) nor with mortality (hazard ratio: 0.73; 95%CI: 0.40-1.34) but was associated with ICU admission (OR: 2.06; 95%CI 1.09-3.92, P = .027) and a longer length of hospital stay. Age was negatively associated with ICU admission and positively associated with death.
CONCLUSIONS
Diabetes was prevalent in a quarter of the patients hospitalized with COVID-19; it was associated with a greater risk of ICU admission but not with a significant elevation in mortality. Further investigation of the relationship between COVID-19 severity and diabetes is warranted.
Identifiants
pubmed: 32683744
doi: 10.1002/dmrr.3388
pmc: PMC7404605
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3388Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
N Engl J Med. 2015 Oct 29;373(18):1720-32
pubmed: 26510021
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
JCI Insight. 2019 Oct 17;4(20):
pubmed: 31550243
Obesity (Silver Spring). 2020 Sep;28(9):1595-1599
pubmed: 32445512
Endocr Rev. 2020 Jun 1;41(3):
pubmed: 32294179
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Clin Infect Dis. 2020 Jul 28;71(15):896-897
pubmed: 32271368
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Diabetes Metab Res Rev. 2020 Mar 31;:e3319
pubmed: 32233013
Diabetes Metab Res Rev. 2021 Mar;37(3):e3388
pubmed: 32683744
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Metabolism. 2020 Jul;108:154262
pubmed: 32422233
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403
pubmed: 32334395
Diabetes Metab Res Rev. 2020 Apr 21;:e3325
pubmed: 32314503
Lancet Diabetes Endocrinol. 2018 Jul;6(7):538-546
pubmed: 29752194
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Am J Physiol Renal Physiol. 2018 Aug 1;315(2):F263-F274
pubmed: 29561187
Obesity (Silver Spring). 2020 Jul;28(7):1195-1199
pubmed: 32271993
JAMA. 2020 May 12;323(18):1769-1770
pubmed: 32208485
Diabetes Metab Res Rev. 2021 Jan;37(1):e3354
pubmed: 32484298
BMJ. 2020 May 22;369:m1985
pubmed: 32444460